June 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Avidity Biosciences, Broadcom and Cara Therapeutics, on Thursday.
HIGHLIGHTS
* Avidity Biosciences Inc : Leerink Partners raises target price to $56 from $38
* Broadcom Inc : TD Cowen raises target price to $1,750 from $1,500
* Cara Therapeutics Inc : Canaccord Genuity cuts to hold from buy
Following is a summary of research actions on U.S. companies reported by Reuters on Thursday. Stock entries are in alphabetical order.
* Amphenol : Evercore ISI adjusts PT to $75 from $150 to reflect 2-for-1 stock split
* Avidity Biosciences Inc : Evercore ISI raises target price to $45 from $40
* Avidity Biosciences Inc : Leerink Partners raises target price to $56 from $38
* Avidity Biosciences Inc : Needham raises target price to $46 from $35
* Avidity Biosciences Inc : Raymond James raises target price to $90 from $66
* Broadcom Inc : Evercore ISI raises target price to $2010 from $1620
* Broadcom Inc : TD Cowen raises target price to $1,750 from $1,500
* Cara Therapeutics Inc : Canaccord Genuity cuts to hold from buy
* Caseys General Stores Inc : Jefferies raises target price to $445 from $342
* Celsius Holdings Inc : TD Cowen cuts target price to $85 from $95
* Charles River Laboratories International Inc : Baird raises PT to $271 from $270
* Corning Inc : Jefferies raises target price to $33.5 from $30
* Enovis Corp : JP Morgan initiates coverage with neutral rating; price target $53
* Lexeo Therapeutics Inc : Baird initiates coverage with outperform rating; PT $28
* Meritage Homes Corp : Evercore ISI raises target price to $219 from $217
* Twist Bioscience Corp : TD Cowen raises target price to $65 from $55
* Williams Companies Inc : RBC raises target price to $44 from $40
(Compiled by Bengaluru Newsroom)
((Diaries@thomsonreuters.com))
Comments